Table 1.
Clinicopathologic Characteristics for MD Anderson and Mayo Clinic Patient Cohorts
| Characteristic | MD Anderson (n=509) | Mayo Clinic (n=464) | P-value |
|---|---|---|---|
|
| |||
| Age | .02 | ||
| median | 54 | 56 | |
| range | 22–84 | 26–88 | |
|
| |||
| Pathologic tumor size (cm) | .04 | ||
| mean | 2.3 | 2.6 | |
| range | 0.1–12.0 | 0.1–15.0 | |
|
| |||
| Histology | <.001 | ||
| IDC | 388 (76%) | 357 (77%) | |
| ILC | 42 (8%) | 95 (20%) | |
| mixed IDC/ILC | 66 (13%) | 12 (3%) | |
| other | 13 (3%) | 0 | |
|
| |||
| Grade | <.001 | ||
| I | 51 (10%) | 107 (23%) | |
| II | 274 (54%) | 261 (56%) | |
| III | 184 (36%) | 96 (21%) | |
|
| |||
| Multifocal disease | 1.0 | ||
| yes | 85 (17%) | 78 (17%) | |
| no | 424 (83%) | 386 (83%) | |
|
| |||
| ER | .46 | ||
| positive | 435 (85%) | 405 (87%) | |
| negative | 74 (15%) | 59 (13%) | |
|
| |||
| PR | <.001 | ||
| positive | 348 (68%) | 380 (82%) | |
| negative | 161 (32%) | 84 (18%) | |
|
| |||
| HER2 | |||
| positive | 96 (19%) | Data not | |
| negative | 413 (81%) | available | |
|
| |||
| LVI | .02 | ||
| present | 189 (37%) | 206 (44%) | |
| absent | 320 (63%) | 258 (56%) | |
|
| |||
| Number of SLN identified | <.001 | ||
| median | 3 | 2 | |
| range | 1–13 | 1–11 | |
|
| |||
| Number of positive SLN | <.001 | ||
| median | 1 | 1 | |
| range | 1–6 | 1–8 | |
|
| |||
| SLN maximum metastasis size (mm) | .36 | ||
| median | 4 | 4.2 | |
| range | .1–25 | .1–26 | |
|
| |||
| Extranodal extension | <.001 | ||
| present | 115 (23%) | 211 (45%) | |
| absent | 394 (77%) | 253 (55%) | |
|
| |||
| Status of non-SLN | <.001 | ||
| positive | 149 (29%) | 202 (44%) | |
| negative | 360 (71%) | 262 (56%) | |
Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor ; PR, progesterone receptor, HER2, HER2/neu ; LVI, lymphovascular invasion ; SLN, sentinel lymph node